International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.
International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.
Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.
Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.
Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.
International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.
Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.
Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.
Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.
An International Open Access Journal Devoted to General Medicine.
Tumor‑associated macrophages suppress estrogen receptor‑β expression in triple‑negative breast cancer through the PI3K/AKT pathway
Triple‑negative breast cancer (TNBC) is a highly aggressive breast cancer subtype with limited therapeutic options. Estrogen receptor (ER)‑β exerts anti‑tumor effects. However, ERβ expression is frequently reduced in TNBC and the mechanisms underlying the downregulation of ERβ in TNBC remain poorly understood. In the present study, findings revealed that tumor‑associated macrophages (TAMs), which are abundant in the tumor microenvironment, suppressed ERβ expression in TNBC cells. The relationship between TAMs and ERβ in TNBC was investigated through bioinformatics analysis, co‑culture and orthotopic mouse models. ERβ expression levels were lower in the TNBC tumors compared with normal tissues. Mechanistically, TAM‑induced activation of the PI3K/AKT pathway suppressed ERβ expression by reducing FOXO3a binding to the ESR2 promoter, whereas inhibition of PI3K/AKT restored ERβ expression. Notably, combined PI3K/AKT pathway inhibition with ERβ activation attenuated TNBC cell metastasis. Overall, findings indicated that TAMs promoted TNBC progression by downregulating ERβ expression through the PI3K/AKT/FOXO3a axis, highlighting the therapeutic potential of combining PI3K/AKT inhibitors with ERβ agonists in TNBC.